Search

Your search keyword '"Ferrante, M."' showing total 2,394 results
Start Over Author "Ferrante, M."
2,394 results on '"Ferrante, M."'

1. Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030

Author

Crocetti, Emanuele, Mallone, Sandra, Pierannunzio, Daniela, Contiero, Paolo, Tagliabue, Giovanna, Memo, Laura, Manneschi, Gianfranco, Ravaioli, Alessandra, Cuccaro, Francesco, Richiardi, Lorenzo, Casella, Claudia, Anna di Prima, Alessia, Maifredi, Giovanni, Lanzoni, Monica, Cirilli, Claudia, Leite, Silvia, Michiara, Maria, Ferraioli, Serena, Zarcone, Maurizio, Vitale, Maria Francesca, Giacomazzi, Erica, Ghisleni, Silvia, Bisceglia, Isabella, Gentilini, Maria A., Vittadello, Fabio, Spata, Eugenia, Marguati, Stefano, Del Riccio, Luciana, Concas, Elisa, Sessa, Alessandra, Colanino, Antonino Ziino, Prazzoli, Rita, Ferrari, Gianfabrizio, Canu, Luisa, Guzzinati, S., Toffolutti, F., Francisci, S., De Paoli, A., Giudici, F., De Angelis, R., Demuru, E., Botta, L., Tavilla, A., Gatta, G., Capocaccia, R., Zorzi, M., Caldarella, A., Bidoli, E., Falcini, F., Bruni, R., Migliore, E., Puppo, A., Ferrante, M., Gasparotti, C., Gambino, M.L., Carrozzi, G., Bianconi, F., Musolino, A., Cavallo, R., Mazzucco, W., Fusco, M., Ballotari, P., Sampietro, G., Ferretti, S., Mangone, L., Mantovani, W., Mian, M., Cascone, G., Manzoni, F., Galasso, R., Piras, D., Pesce, M.T., Bella, F., Seghini, P., Fanetti, A.C., Pinna, P., Serraino, D., Rossi, S., and Dal Maso, L.

Published
2024
Full Text
View/download PDF

3. T.05.2: REDUCING DIAGNOSTIC DELAY OF EXTRA-INTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A COMPARATIVE STUDY BETWEEN A MULTIDISCIPLINARY IMMUNE-MEDIATED DISEASES OUTPATIENT CLINIC AND CONVENTIONAL REFERRAL SPECIALISTS

Author

Nardone, O.M., primary, Calabrese, G., additional, Peluso, R., additional, Foglia, F., additional, Megna, M., additional, Cacciapuoti, S., additional, La Mantia, A., additional, D'Alessandro, E., additional, Ferrante, M., additional, Villani, G.D., additional, Testa, A., additional, Bonacci, L., additional, Leo, C., additional, Rispo, A., additional, and Castiglione, F., additional

Published
2024
Full Text
View/download PDF

5. Exploring Pediatric Secondary Osteoporosis: The Red Flag of Several Systemic Diseases.

Author

Mangiatordi, S., Ferrante, M., Raspo, A., Capriati, B., Stellacci, G., Urbano, F., Faienza, M. F., and Francavilla, M.

Subjects
*OSTEOPOROSIS, *VITAMIN D deficiency, *DUAL-energy X-ray absorptiometry, *ICHTHYOSIS
Abstract

This article explores the topic of pediatric secondary osteoporosis, specifically focusing on vertebral fractures (VFs) and the importance of investigating osteoporosis in children with isolated back pain, as it may indicate underlying systemic diseases. The most common causes of secondary osteoporosis in children are endocrine disorders, gastrointestinal disorders, rheumatologic, oncologic, and renal diseases, medications such as glucocorticoids, and immobility. The diagnosis of childhood osteoporosis relies on dual-energy X-ray absorptiometry (DEXA) and conventional spine radiographs. The article presents two case studies that highlight the importance of early diagnosis and a multidisciplinary approach involving radiologists, pediatricians, and orthopedics in recognizing and treating underlying systemic diseases. [Extracted from the article]

Published
2024
Full Text
View/download PDF

7. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study

Author

Ferrante, M, primary, Danese, S, additional, Chen, M, additional, D'Haens, G, additional, Ghosh, S, additional, Hisamatsu, T, additional, Jairath, V, additional, Kierkus, J, additional, Peyrin-Biroulet, L, additional, Siegmund, B, additional, Bragg, S M, additional, Crandall, W, additional, Hunter Gibble, T, additional, Lin, Z, additional, Ugolini Lopes, M, additional, Morris, N, additional, Carlier, H, additional, and Sands, B, additional

Published
2024
Full Text
View/download PDF

9. OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study

Author

Jairath, V, primary, Sands, B E, additional, Bossuyt, P, additional, Farraye, F, additional, Ferrante, M, additional, Hisamatsu, T, additional, Kaser, A, additional, Kierkus, J, additional, Laharie, D, additional, Reinisch, W, additional, Siegmund, B, additional, Bragg, S M, additional, Hon, E, additional, Lin, Z, additional, Ugolini Lopes, M, additional, Morris, N, additional, Protic, M, additional, and Danese, S, additional

Published
2024
Full Text
View/download PDF

10. DOP48 Faecal microbiota transplantation in active Ulcerative Colitis: Key lessons from a randomized controlled trial halted for futility

Author

Deleu, S, primary, Caenepeel, C, additional, Vazquez Castellanos, J F, additional, Arnauts, K, additional, Braekeleire, S, additional, Machiels, K, additional, Baert, F, additional, Mana, F, additional, Pouillon, L, additional, Hindryckx, P, additional, Lobaton Ortega, T, additional, Louis, E, additional, Franchimont, D, additional, Verstockt, B, additional, Ferrante, M, additional, Sabino, J, additional, Vieira-Silva, S, additional, Falony, G, additional, Raes, J, additional, and Vermeire, S, additional

Published
2024
Full Text
View/download PDF

11. DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

Author

Ferrante, M, primary, Panaccione, R, additional, Colombel, J F, additional, Dubinsky, M, additional, Hisamatsu, T, additional, Lindsay, J O, additional, Song, A, additional, Neimark, E, additional, Zhang, Y, additional, Kligys, K, additional, Crowley, J, additional, Duan, W R, additional, and D’Haens, G, additional

Published
2024
Full Text
View/download PDF

12. P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

Author

Panaccione, R, primary, Louis, E, additional, Colombel, J F, additional, D'Haens, G, additional, Peyrin-Biroulet, L, additional, Dubinsky, M, additional, Takeuchi, K, additional, Kalabic, J, additional, Levine, P, additional, Neimark, E, additional, Chen, S, additional, Cheng, L, additional, Duan, W R, additional, Vladea, R, additional, Hecht, P M, additional, Sanchez Gonzalez, Y, additional, Schreiber, S, additional, and Ferrante, M, additional

Published
2024
Full Text
View/download PDF

13. P1128 Reducing diagnostic delay of Extra-Intestinal Manifestations in patients with Inflammatory Bowel Disease: a comparative study between a multidisciplinary immune-mediated diseases outpatient clinic and conventional referral specialists

Author

Nardone, O M, primary, Calabrese, G, additional, Peluso, R, additional, Foglia, F, additional, Megna, M, additional, Cacciapuoti, S, additional, La Mantia, A, additional, D'Alessandro, E, additional, Ferrante, M, additional, Villani, G, additional, Testa, A, additional, Bonacci, L, additional, Leo, C, additional, Rispo, A, additional, and Castiglione, F, additional

Published
2024
Full Text
View/download PDF

14. DOP73 Early biological use in a Belgian, prospective inception cohort of patients with Inflammatory Bowel Disease: the PANTHER cohort

Author

Verstockt, S, primary, Glorieus, E, additional, De Wolf, M, additional, Lenfant, M, additional, Barbaraci, M, additional, Sabino, J, additional, Ferrante, M, additional, Geldof, J, additional, Verstockt, B, additional, Laukens, D, additional, Cleynen, I, additional, Vandermeulen, L, additional, Lobaton, T, additional, and Vermeire, S, additional

Published
2024
Full Text
View/download PDF

15. P1083 Patient preferences for Inflammatory Bowel Disease treatments: an international survey using a discrete choice experiment in partnership with EFCCA

Author

Schoefs, E, primary, Janssens, R, additional, Gutiérrez-Vargas, Á A, additional, Ferrante, M, additional, Sabino, J, additional, Verstockt, B, additional, Avedano, L, additional, De Rocchis, M S, additional, Sajak-Szczerba, M, additional, Saldaña, R, additional, Straetemans, N, additional, Vandebroek, M, additional, Vermeire, S, additional, and Huys, I, additional

Published
2024
Full Text
View/download PDF

19. OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study

Author

Louis, E, primary, Panaccione, R, additional, Parkes, G, additional, Peyrin-Biroulet, L, additional, Ferrante, M, additional, Hisamatsu, T, additional, Siegmund, B, additional, Kalabic, J, additional, Levine, P, additional, Neimark, E, additional, Wallace, K, additional, Chen, S, additional, Cheng, L, additional, Duan, W R, additional, Armuzzi, A, additional, Biederman, L, additional, Loftus, E, additional, Melmed, G, additional, and Schreiber, S, additional

Published
2024
Full Text
View/download PDF

21. DOP86 FOod Additives on the Mucosal barrier study (FOAM): Effect of five emulsifiers on inflammation, intestinal permeability, and the microbiome: preliminary results

Author

Wellens, J, primary, Vanderstappen, J, additional, Hoekx, S, additional, Vissers, E, additional, Luppens, M, additional, Raes, J, additional, Verstockt, B, additional, Ferrante, M, additional, Verbeke, K, additional, Matthys, C, additional, Vermeire, S, additional, and Sabino, J, additional

Published
2024
Full Text
View/download PDF

22. P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study

Author

D'Haens, G, primary, Sands, B E, additional, Ferrante, M, additional, Matsuoka, K, additional, Lindsay, J O, additional, Blumenstein, I, additional, Mehra, D, additional, Charles, L, additional, Cetin, V, additional, Petersen, A, additional, Wu, H, additional, Wang, D, additional, Jain, A, additional, and Hanauer, S B, additional

Published
2024
Full Text
View/download PDF

24. OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial

Author

Travis, S, primary, Hisamatsu, T, additional, Fischer, M, additional, Dubinsky, M, additional, Jairath, V, additional, Chen, M, additional, Ferrante, M, additional, Peyrin-Biroulet, L, additional, Siegmund, B, additional, Hunter Gibble, T, additional, Lin, Z, additional, Protic, M, additional, Morris, N, additional, and Ghosh, S, additional

Published
2024
Full Text
View/download PDF

28. OP36 Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

Author

Dubinsky, M C, primary, D’Haens, G, additional, Atreya, R, additional, Abraham, B, additional, Armuzzi, A, additional, Arguelles-Arias, F, additional, Lindsay, J O, additional, Patel, K, additional, Neimark, E, additional, Huang, X, additional, Anschutz, T, additional, van Haaren, S, additional, O’Brien, D, additional, and Ferrante, M, additional

Published
2024
Full Text
View/download PDF

29. DOP03 Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey on processes and outcomes

Author

Walsh, A, primary, Fidalgo, C, additional, Adamina, M, additional, Barreiro de Acosta, M, additional, Burisch, J, additional, Drobne, D, additional, Faiz, O, additional, Ferrante, M, additional, Godny, L, additional, Iacucci, M, additional, Jäghult, S, additional, Restellini, S, additional, Rosini, F, additional, Shouval, D, additional, Yanai, H, additional, and Fiorino, G, additional

Published
2024
Full Text
View/download PDF

32. DOP66 INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s Disease and complex perianal fistulas

Author

Fathallah, N, primary, Zmora, O, additional, Baumgart, D C, additional, Faubion, W, additional, Ferrante, M, additional, Gecse, K, additional, Wright, E, additional, McKay, C, additional, Ren, K, additional, Punchard, M, additional, Zhang, B, additional, and Panés, J, additional

Published
2024
Full Text
View/download PDF

34. PCR60 Shared Decision Making in Inflammatory Bowel Disease Clinical Practice: What Are the Experiences, Barriers, and Opportunities According to Patients and Healthcare Professionals?

Author

Schoefs, E., primary, Michiels, L., additional, Vermeire, S., additional, Ferrante, M., additional, Verstockt, B., additional, Sabino, J., additional, Debrun, L., additional, Loddewijkx, E., additional, Straetemans, N., additional, Huys, I., additional, and Janssens, R., additional

Published
2023
Full Text
View/download PDF

35. Chronic Antibiotic-Refractory Pouchitis: Management Challenges

Author

Outtier A and Ferrante M

Subjects
chronic antibiotic-refractory pouchitis, inflammatory bowel disease, biologics, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

An Outtier, Marc Ferrante Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, BelgiumCorrespondence: Marc FerranteDepartment of Gastroenterology and Hepatology, University Hospitals Leuven, Herestraat 49, Leuven, 3000, BelgiumTel +32 16 34 42 18Fax +32 16 33 07 23Email marc.ferrante@uzleuven.beBackground: Pouchitis is the most common long-term complication in patients with ulcerative colitis who underwent restorative proctocolectomy with ileal pouch-anal anastomosis. The incidence of acute pouchitis is 20% after 1 year and up to 40% after 5 years. Chronic antibiotic-refractory pouchitis develops in approximately 10% of patients.Aim: To present a narrative review of published literature regarding the management of chronic antibiotic-refractory pouchitis.Methods: Current relevant literature was summarized and critically evaluated.Results: Clear definitions should be used to classify pouchitis into acute versus chronic, and responsive versus dependent versus refractory to antibiotics. Before treatment is started for chronic antibiotic-refractory pouchitis, secondary causes should be ruled out. There is a need for validated scoring systems to measure the severity of the disease. Because chronic antibiotic-refractory pouchitis is a rare condition, only small studies with often a poor study design have been performed. Treatments with antibiotics, aminosalicylates, steroids, immunomodulators and biologics have shown to be effective and safe for chronic antibiotic-refractory pouchitis. Also, treatments with AST-120, hyperbaric oxygen therapy, tacrolimus enemas, and granulocyte and monocyte apheresis suggested some efficacy.Conclusion: The available data are weak but suggest that therapeutic options for chronic antibiotic-refractory pouchitis are similar to the treatment strategies for inflammatory bowel diseases. However, randomized controlled trials are warranted to further identify the best treatment options in this patient population.Keywords: chronic antibiotic-refractory pouchitis, inflammatory bowel disease, biologics

Published
2021

36. High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn’s Disease in a Randomized Placebo-Controlled Trial

Author

Bemelman, W., Buskens, C., Clasquin, E., De Bruyn, J., D’Haens, G., Duijvestein, M., Van der Bilt, J., Ferreira, B., Mulder, S., West, R., Dijkstra, G., Engelsman, A., Lange, J., Homans, L., Witteman, B., Eroglu-Berger, A., Russel, M., Jansen, J., Schakel–van den Berge, T., Cuppen, S., Hoentjen, F., Van Esch, A., De Jong, D.J., Mahmmod, N., Hove.P. De Lange, W. Ten, Mallant, R., Houben, P., Ferrante, M., Vermeire, S., Outtier, A., Hermans, T., Lefrère, J., D’Hoore, A., Asnong, K., Bossuyt, P., Van de Schoot, I., Claerbout, B., Lambrecht, G., Boutaffala, L., Guebelle, C., Louis, E., Franchimont, D., Wambacq, V., Colard, A., Deflandre, A., de Bruyn, Jessica R., Bossuyt, Peter, Ferrante, Marc, West, Rachel L., Dijkstra, Gerard, Witteman, Ben J., Wildenberg, Manon, Hoentjen, Frank, Franchimont, Denis, Clasquin, Esmé, van der Bilt, Jarmila D., Tollens, Tim, Bemelman, Willem A., D’Hoore, Andre, Duijvestein, Marjolijn, and D’Haens, Geert R.

Published
2021
Full Text
View/download PDF

38. Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case–Control Study

Author

Signorelli SS, Oliveri Conti G, Fiore M, Cangiano F, Zuccarello P, Gaudio A, and Ferrante M

Subjects
deep vein thrombosis, microparticles, platelet, extracellular vescicles, biomarkers, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Salvatore Santo Signorelli,1 Gea Oliveri Conti,2 Maria Fiore,2 Federica Cangiano,2 Pietro Zuccarello,2 Agostino Gaudio,1 Margherita Ferrante2 1Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; 2Department of Medical, Surgical Sciences and Advanced Technologies, G.F. Ingrassia, University of Catania, Catania, ItalyCorrespondence: Salvatore Santo SignorelliDepartment of Clinical and Experimental Medicine, University of Catania, via S.Sofia, Catania I-95123, ItalyTel +39 0953782545Fax +39 0953782376Email ssignore@unict.itIntroduction: The role of platelets (Ps) and platelet-derived microparticles (MPs) in venous thromboembolism (VTE) is still being debated.Methods: We measured MPs, velocity of thrombin formation (PiCT) and phospholipid generation (PLPs) in 40 patients with unprovoked deep vein thrombosis (DVT), who were compared with 40 healthy controls.Results: MPs were higher in DVT (7.12 nM; 25th– 75th percentile 5.26– 9.12) than in controls (5.45 nM; 25th– 75th percentile 1.67– 8.96) (p = 0.19). PiCT velocity was lower in DVT (1.87 sec; 25th– 75th percentile 1.75– 1.93 sec) compared with controls (1.95 sec; 25th– 75th percentile 1.84– 2.24 sec) (p = 0.04). PLPs were higher in DVT (77.03 μg/mL; 25th– 75th percentile 72.12– 103.59 μg/mL) compared with controls (68.65 μg/mL, 25th– 75th percentile 55.31– 78.20 μg/mL) (p = 0.02).Discussion: We hypothesize that MPs could be integrated with the lab network assay in evaluating Ps’ role as an activated procoagulative condition. We encourage research on Ps and P-derived microvesicle pathways in patients with unprovoked DVT and not only in patients with cancer-induced DVT.Keywords: deep vein thrombosis, microparticles, platelet, extracellular vesicles, biomarkers

Published
2020

45. From shallow to very shallow image of the highly active Kefalonia - Zakynthos fault system.

Author

Loreto, M. F., Nomikou, P., Ferrante, V., Argnani, A., Ferrante, M. G., Accettella, D., Ametller, R., Bubbi, A., Cova, A., Dal Cin, M., Facchin, L., Ferrante, M., Fiorentino, A., Iurcev, M., Lampidou, D., Merino, I., Nikoli, E., Ligi, M., Muccini, F., and Palmiotto, C.

Subjects
GEOLOGIC faults, SEDIMENTS, ROCK deformation, GEOMORPHOLOGY
Published
2023

49. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease–a Case Series

Author

Vieujean, S, Moens, A, Hassid, D, Rothfuss, K, Savarino, E, Vavricka, S R, Reenaers, C, Jacobsen, B, Allez, M, Ferrante, M, Rahier, Jean-François, ECCO CONFER investigators, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service de gastro-entérologie

Subjects
inflammatory bowel disease, Gastroenterology, General Medicine, Pneumocystis jirovecii pneumonia
Abstract

Background and aim: Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP.Methods: PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organisation. Clinical data were provided through a case report form.Results: In all, 18 PJP episodes were reported in 17 IBD patients [10 ulcerative colitis and seven Crohn's disease]. The median age at PJP diagnosis was 55 years (interquartile range [IQR], 40-68 years]. Two PJP [11.1%] occurred in patients on triple immunosuppression, 10 patients [55.6%] had double immunosuppressive treatment, four patients [22.2%] had monotherapy and two PJP occurred in absence of immunosuppressive treatment [one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation]. Immunosuppressive therapies included steroids [n = 12], thiopurines [n = 10], infliximab [n = 4], ciclosporin [n = 2], methotrexate [n = 1], and tacrolimus [n = 1]. None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulphamethoxazole or atovaquone and an intensive care unit [ICU] stay was required in seven cases. Two patients [aged 71 and 32 years] died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others.Conclusion: This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy. Background and aim: Pneumocystis jirovecii pneumonia [PJP] is a very rare, potentially life-threatening pulmonary fungal infection that occurs in immunocompromised individuals including patients with inflammatory bowel disease [IBD]. Our aim was to describe immunosuppressive treatment exposure as well as the outcome in IBD patients with PJP.Methods: PJP cases were retrospectively collected through the COllaborative Network For Exceptionally Rare case reports of the European Crohn's and Colitis Organisation. Clinical data were provided through a case report form.Results: In all, 18 PJP episodes were reported in 17 IBD patients [10 ulcerative colitis and seven Crohn's disease]. The median age at PJP diagnosis was 55 years (interquartile range [IQR], 40-68 years]. Two PJP [11.1%] occurred in patients on triple immunosuppression, 10 patients [55.6%] had double immunosuppressive treatment, four patients [22.2%] had monotherapy and two PJP occurred in absence of immunosuppressive treatment [one in a human immunodeficiency virus patient and one in a patient with a history of autologous stem cell transplantation]. Immunosuppressive therapies included steroids [n = 12], thiopurines [n = 10], infliximab [n = 4], ciclosporin [n = 2], methotrexate [n = 1], and tacrolimus [n = 1]. None of the patients diagnosed with PJP had received prophylaxis. All patients were treated by trimethoprim/sulphamethoxazole or atovaquone and an intensive care unit [ICU] stay was required in seven cases. Two patients [aged 71 and 32 years] died, and one patient had a recurrent episode 16 months after initial treatment. Evolution was favourable for the others.Conclusion: This case series reporting potentially fatal PJP highlights the need for adjusted prophylactic therapy in patients with IBD on immunosuppressive therapy.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results